Solventum Corporation (SOLV) Stock Competitors & Peer Comparison
See (SOLV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SOLV | $78.27 | -0.10% | 13.6B | 12.54 | $6.24 | N/A |
| HCA | $410.50 | +4.39% | 91.1B | 14.17 | $28.96 | +0.73% |
| THC | $203.72 | +6.55% | 17.5B | 11.82 | $17.24 | N/A |
| TALKW | $0.00 | +0.00% | 15.3B | 0.06 | $0.06 | N/A |
| DVA | $234.91 | +3.02% | 15.1B | 20.03 | $11.73 | N/A |
| FMS | $23.53 | +2.93% | 12.6B | 9.34 | $2.52 | +3.67% |
| EHC | $106.46 | +5.00% | 10.6B | 18.71 | $5.69 | +0.71% |
| UHS | $158.33 | +5.15% | 9.9B | 7.02 | $22.54 | +0.51% |
| ENSG | $168.22 | +2.06% | 9.8B | 24.38 | $6.90 | +0.15% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
SOLV vs HCA Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, HCA has a market cap of 91.1B. Regarding current trading prices, SOLV is priced at $78.27, while HCA trades at $410.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas HCA's P/E ratio is 14.17. In terms of profitability, SOLV's ROE is +0.31%, compared to HCA's ROE of -1.23%. Regarding short-term risk, SOLV is less volatile compared to HCA. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check HCA's competition here
SOLV vs THC Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, THC has a market cap of 17.5B. Regarding current trading prices, SOLV is priced at $78.27, while THC trades at $203.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas THC's P/E ratio is 11.82. In terms of profitability, SOLV's ROE is +0.31%, compared to THC's ROE of +0.41%. Regarding short-term risk, SOLV is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check THC's competition here
SOLV vs TALKW Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, TALKW has a market cap of 15.3B. Regarding current trading prices, SOLV is priced at $78.27, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas TALKW's P/E ratio is 0.06. In terms of profitability, SOLV's ROE is +0.31%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, SOLV is more volatile compared to TALKW. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check TALKW's competition here
SOLV vs DVA Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, DVA has a market cap of 15.1B. Regarding current trading prices, SOLV is priced at $78.27, while DVA trades at $234.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas DVA's P/E ratio is 20.03. In terms of profitability, SOLV's ROE is +0.31%, compared to DVA's ROE of -1.33%. Regarding short-term risk, SOLV is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check DVA's competition here
SOLV vs FMS Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, FMS has a market cap of 12.6B. Regarding current trading prices, SOLV is priced at $78.27, while FMS trades at $23.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas FMS's P/E ratio is 9.34. In terms of profitability, SOLV's ROE is +0.31%, compared to FMS's ROE of +0.07%. Regarding short-term risk, SOLV is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check FMS's competition here
SOLV vs EHC Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, EHC has a market cap of 10.6B. Regarding current trading prices, SOLV is priced at $78.27, while EHC trades at $106.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas EHC's P/E ratio is 18.71. In terms of profitability, SOLV's ROE is +0.31%, compared to EHC's ROE of +0.25%. Regarding short-term risk, SOLV is less volatile compared to EHC. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check EHC's competition here
SOLV vs UHS Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, UHS has a market cap of 9.9B. Regarding current trading prices, SOLV is priced at $78.27, while UHS trades at $158.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas UHS's P/E ratio is 7.02. In terms of profitability, SOLV's ROE is +0.31%, compared to UHS's ROE of +0.21%. Regarding short-term risk, SOLV is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check UHS's competition here
SOLV vs ENSG Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, ENSG has a market cap of 9.8B. Regarding current trading prices, SOLV is priced at $78.27, while ENSG trades at $168.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas ENSG's P/E ratio is 24.38. In terms of profitability, SOLV's ROE is +0.31%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, SOLV is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check ENSG's competition here
SOLV vs OSH Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, SOLV is priced at $78.27, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas OSH's P/E ratio is -17.65. In terms of profitability, SOLV's ROE is +0.31%, compared to OSH's ROE of +4.64%. Regarding short-term risk, SOLV is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check OSH's competition here
SOLV vs CHE Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, CHE has a market cap of 6.5B. Regarding current trading prices, SOLV is priced at $78.27, while CHE trades at $489.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas CHE's P/E ratio is 22.66. In terms of profitability, SOLV's ROE is +0.31%, compared to CHE's ROE of +0.25%. Regarding short-term risk, SOLV is less volatile compared to CHE. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check CHE's competition here
SOLV vs LHCG Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, SOLV is priced at $78.27, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas LHCG's P/E ratio is 82.83. In terms of profitability, SOLV's ROE is +0.31%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, SOLV is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check LHCG's competition here
SOLV vs MMED Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, MMED has a market cap of 4.4B. Regarding current trading prices, SOLV is priced at $78.27, while MMED trades at $15.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas MMED's P/E ratio is -10.06. In terms of profitability, SOLV's ROE is +0.31%, compared to MMED's ROE of -0.15%. Regarding short-term risk, SOLV is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check MMED's competition here
SOLV vs LFST Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, LFST has a market cap of 4.4B. Regarding current trading prices, SOLV is priced at $78.27, while LFST trades at $11.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas LFST's P/E ratio is 179.54. In terms of profitability, SOLV's ROE is +0.31%, compared to LFST's ROE of +0.02%. Regarding short-term risk, SOLV is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check LFST's competition here
SOLV vs BKD Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, BKD has a market cap of 3.8B. Regarding current trading prices, SOLV is priced at $78.27, while BKD trades at $15.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas BKD's P/E ratio is -27.36. In terms of profitability, SOLV's ROE is +0.31%, compared to BKD's ROE of +401.19%. Regarding short-term risk, SOLV is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check BKD's competition here
SOLV vs OPCH Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, OPCH has a market cap of 3.4B. Regarding current trading prices, SOLV is priced at $78.27, while OPCH trades at $21.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas OPCH's P/E ratio is 12.73. In terms of profitability, SOLV's ROE is +0.31%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, SOLV is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check OPCH's competition here
SOLV vs NHC Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, NHC has a market cap of 3.4B. Regarding current trading prices, SOLV is priced at $78.27, while NHC trades at $218.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas NHC's P/E ratio is 31.34. In terms of profitability, SOLV's ROE is +0.31%, compared to NHC's ROE of +0.12%. Regarding short-term risk, SOLV is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check NHC's competition here
SOLV vs AMED Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, SOLV is priced at $78.27, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas AMED's P/E ratio is 39.30. In terms of profitability, SOLV's ROE is +0.31%, compared to AMED's ROE of +0.11%. Regarding short-term risk, SOLV is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check AMED's competition here
SOLV vs ACHC Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, ACHC has a market cap of 2.9B. Regarding current trading prices, SOLV is priced at $78.27, while ACHC trades at $31.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas ACHC's P/E ratio is 16.04. In terms of profitability, SOLV's ROE is +0.31%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, SOLV is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check ACHC's competition here
SOLV vs ASTH Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, ASTH has a market cap of 2.4B. Regarding current trading prices, SOLV is priced at $78.27, while ASTH trades at $49.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas ASTH's P/E ratio is 33.22. In terms of profitability, SOLV's ROE is +0.31%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, SOLV is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check ASTH's competition here
SOLV vs SGRY Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, SGRY has a market cap of 2.3B. Regarding current trading prices, SOLV is priced at $78.27, while SGRY trades at $17.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas SGRY's P/E ratio is 44.18. In terms of profitability, SOLV's ROE is +0.31%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, SOLV is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check SGRY's competition here
SOLV vs MD Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, MD has a market cap of 2.2B. Regarding current trading prices, SOLV is priced at $78.27, while MD trades at $26.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas MD's P/E ratio is 12.50. In terms of profitability, SOLV's ROE is +0.31%, compared to MD's ROE of +0.20%. Regarding short-term risk, SOLV is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check MD's competition here
SOLV vs SEM Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, SOLV is priced at $78.27, while SEM trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas SEM's P/E ratio is 15.43. In terms of profitability, SOLV's ROE is +0.31%, compared to SEM's ROE of +0.08%. Regarding short-term risk, SOLV is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check SEM's competition here
SOLV vs AVAH Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, AVAH has a market cap of 2B. Regarding current trading prices, SOLV is priced at $78.27, while AVAH trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas AVAH's P/E ratio is 13.38. In terms of profitability, SOLV's ROE is +0.31%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, SOLV is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check AVAH's competition here
SOLV vs ADUS Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, ADUS has a market cap of 2B. Regarding current trading prices, SOLV is priced at $78.27, while ADUS trades at $105.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas ADUS's P/E ratio is 16.33. In terms of profitability, SOLV's ROE is +0.31%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, SOLV is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check ADUS's competition here
SOLV vs AGL Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, AGL has a market cap of 1.9B. Regarding current trading prices, SOLV is priced at $78.27, while AGL trades at $111.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas AGL's P/E ratio is -10.86. In terms of profitability, SOLV's ROE is +0.31%, compared to AGL's ROE of -1.46%. Regarding short-term risk, SOLV is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check AGL's competition here
SOLV vs AMEH Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, SOLV is priced at $78.27, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas AMEH's P/E ratio is 39.25. In terms of profitability, SOLV's ROE is +0.31%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, SOLV is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check AMEH's competition here
SOLV vs HCSG Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, HCSG has a market cap of 1.7B. Regarding current trading prices, SOLV is priced at $78.27, while HCSG trades at $25.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas HCSG's P/E ratio is 20.12. In terms of profitability, SOLV's ROE is +0.31%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, SOLV is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check HCSG's competition here
SOLV vs INNV Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, INNV has a market cap of 1.6B. Regarding current trading prices, SOLV is priced at $78.27, while INNV trades at $11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas INNV's P/E ratio is -133.22. In terms of profitability, SOLV's ROE is +0.31%, compared to INNV's ROE of -0.09%. Regarding short-term risk, SOLV is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check INNV's competition here
SOLV vs ARDT Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, ARDT has a market cap of 1.5B. Regarding current trading prices, SOLV is priced at $78.27, while ARDT trades at $10.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas ARDT's P/E ratio is 6.56. In terms of profitability, SOLV's ROE is +0.31%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, SOLV is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check ARDT's competition here
SOLV vs AMN Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, AMN has a market cap of 1.3B. Regarding current trading prices, SOLV is priced at $78.27, while AMN trades at $34.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas AMN's P/E ratio is 11.54. In terms of profitability, SOLV's ROE is +0.31%, compared to AMN's ROE of -0.05%. Regarding short-term risk, SOLV is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check AMN's competition here
SOLV vs PNTG Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, PNTG has a market cap of 1.3B. Regarding current trading prices, SOLV is priced at $78.27, while PNTG trades at $38.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas PNTG's P/E ratio is 31.32. In terms of profitability, SOLV's ROE is +0.31%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, SOLV is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check PNTG's competition here
SOLV vs CMPS Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, CMPS has a market cap of 1.3B. Regarding current trading prices, SOLV is priced at $78.27, while CMPS trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas CMPS's P/E ratio is -8.25. In terms of profitability, SOLV's ROE is +0.31%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, SOLV is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check CMPS's competition here
SOLV vs BKDT Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, SOLV is priced at $78.27, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas BKDT's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, SOLV is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check BKDT's competition here
SOLV vs USPH Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, USPH has a market cap of 1.1B. Regarding current trading prices, SOLV is priced at $78.27, while USPH trades at $72.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas USPH's P/E ratio is 27.83. In terms of profitability, SOLV's ROE is +0.31%, compared to USPH's ROE of +0.00%. Regarding short-term risk, SOLV is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check USPH's competition here
SOLV vs TALK Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, TALK has a market cap of 871.1M. Regarding current trading prices, SOLV is priced at $78.27, while TALK trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas TALK's P/E ratio is 766.96. In terms of profitability, SOLV's ROE is +0.31%, compared to TALK's ROE of +0.01%. Regarding short-term risk, SOLV is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check TALK's competition here
SOLV vs SNDA Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, SNDA has a market cap of 844.2M. Regarding current trading prices, SOLV is priced at $78.27, while SNDA trades at $42.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas SNDA's P/E ratio is -7.82. In terms of profitability, SOLV's ROE is +0.31%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, SOLV is more volatile compared to SNDA. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check SNDA's competition here
SOLV vs FSHCX Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, FSHCX has a market cap of 834.6M. Regarding current trading prices, SOLV is priced at $78.27, while FSHCX trades at $122.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas FSHCX's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to FSHCX's ROE of N/A. Regarding short-term risk, SOLV is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check FSHCX's competition here
SOLV vs EHAB Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, SOLV is priced at $78.27, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas EHAB's P/E ratio is -197.14. In terms of profitability, SOLV's ROE is +0.31%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, SOLV is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check EHAB's competition here
SOLV vs GMRS Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, GMRS has a market cap of 662.9M. Regarding current trading prices, SOLV is priced at $78.27, while GMRS trades at $14.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas GMRS's P/E ratio is 6.45. In terms of profitability, SOLV's ROE is +0.31%, compared to GMRS's ROE of +1.01%. Regarding short-term risk, SOLV is less volatile compared to GMRS. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check GMRS's competition here
SOLV vs TOIIW Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, TOIIW has a market cap of 646.7M. Regarding current trading prices, SOLV is priced at $78.27, while TOIIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas TOIIW's P/E ratio is -0.15. In terms of profitability, SOLV's ROE is +0.31%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, SOLV is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check TOIIW's competition here
SOLV vs CYH Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, CYH has a market cap of 549.6M. Regarding current trading prices, SOLV is priced at $78.27, while CYH trades at $3.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas CYH's P/E ratio is 5.34. In terms of profitability, SOLV's ROE is +0.31%, compared to CYH's ROE of +0.06%. Regarding short-term risk, SOLV is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check CYH's competition here
SOLV vs TOI Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, TOI has a market cap of 527.9M. Regarding current trading prices, SOLV is priced at $78.27, while TOI trades at $5.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas TOI's P/E ratio is -14.67. In terms of profitability, SOLV's ROE is +0.31%, compared to TOI's ROE of +3.27%. Regarding short-term risk, SOLV is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check TOI's competition here
SOLV vs VMD Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, VMD has a market cap of 460.8M. Regarding current trading prices, SOLV is priced at $78.27, while VMD trades at $12.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas VMD's P/E ratio is 32.49. In terms of profitability, SOLV's ROE is +0.31%, compared to VMD's ROE of +0.11%. Regarding short-term risk, SOLV is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check VMD's competition here
SOLV vs MCTA Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, SOLV is priced at $78.27, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas MCTA's P/E ratio is 419.36. In terms of profitability, SOLV's ROE is +0.31%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, SOLV is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check MCTA's competition here
SOLV vs CCRN Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, CCRN has a market cap of 426.4M. Regarding current trading prices, SOLV is priced at $78.27, while CCRN trades at $13.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas CCRN's P/E ratio is -188.57. In terms of profitability, SOLV's ROE is +0.31%, compared to CCRN's ROE of -0.27%. Regarding short-term risk, SOLV is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check CCRN's competition here
SOLV vs AUNA Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, AUNA has a market cap of 390.1M. Regarding current trading prices, SOLV is priced at $78.27, while AUNA trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas AUNA's P/E ratio is 4.75. In terms of profitability, SOLV's ROE is +0.31%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, SOLV is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check AUNA's competition here
SOLV vs AIRS Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, AIRS has a market cap of 318.9M. Regarding current trading prices, SOLV is priced at $78.27, while AIRS trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas AIRS's P/E ratio is -150.67. In terms of profitability, SOLV's ROE is +0.31%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, SOLV is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check AIRS's competition here
SOLV vs CSU Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, SOLV is priced at $78.27, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas CSU's P/E ratio is 0.67. In terms of profitability, SOLV's ROE is +0.31%, compared to CSU's ROE of -0.51%. Regarding short-term risk, SOLV is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check CSU's competition here
SOLV vs JYNT Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, JYNT has a market cap of 127.9M. Regarding current trading prices, SOLV is priced at $78.27, while JYNT trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas JYNT's P/E ratio is 89.70. In terms of profitability, SOLV's ROE is +0.31%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, SOLV is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check JYNT's competition here
SOLV vs NAKAW Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, SOLV is priced at $78.27, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas NAKAW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, SOLV is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check NAKAW's competition here
SOLV vs FVE Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, SOLV is priced at $78.27, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas FVE's P/E ratio is -5.64. In terms of profitability, SOLV's ROE is +0.31%, compared to FVE's ROE of -0.15%. Regarding short-term risk, SOLV is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check FVE's competition here
SOLV vs KDLYW Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, SOLV is priced at $78.27, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas KDLYW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, SOLV is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check KDLYW's competition here
SOLV vs BTMD Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, BTMD has a market cap of 95.7M. Regarding current trading prices, SOLV is priced at $78.27, while BTMD trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas BTMD's P/E ratio is 4.93. In terms of profitability, SOLV's ROE is +0.31%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, SOLV is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check BTMD's competition here
SOLV vs NAKA Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, NAKA has a market cap of 67.2M. Regarding current trading prices, SOLV is priced at $78.27, while NAKA trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas NAKA's P/E ratio is -0.21. In terms of profitability, SOLV's ROE is +0.31%, compared to NAKA's ROE of -0.85%. Regarding short-term risk, SOLV is less volatile compared to NAKA. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check NAKA's competition here
SOLV vs DCGO Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, DCGO has a market cap of 54.9M. Regarding current trading prices, SOLV is priced at $78.27, while DCGO trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas DCGO's P/E ratio is -0.64. In terms of profitability, SOLV's ROE is +0.31%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, SOLV is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check DCGO's competition here
SOLV vs ALR Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, SOLV is priced at $78.27, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas ALR's P/E ratio is -1.11. In terms of profitability, SOLV's ROE is +0.31%, compared to ALR's ROE of -0.15%. Regarding short-term risk, SOLV is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check ALR's competition here
SOLV vs PIII Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, PIII has a market cap of 37.2M. Regarding current trading prices, SOLV is priced at $78.27, while PIII trades at $11.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas PIII's P/E ratio is -0.28. In terms of profitability, SOLV's ROE is +0.31%, compared to PIII's ROE of +1.85%. Regarding short-term risk, SOLV is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check PIII's competition here
SOLV vs IMAC Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, SOLV is priced at $78.27, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas IMAC's P/E ratio is -2.27. In terms of profitability, SOLV's ROE is +0.31%, compared to IMAC's ROE of +5.81%. Regarding short-term risk, SOLV is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check IMAC's competition here
SOLV vs CCEL Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, CCEL has a market cap of 28M. Regarding current trading prices, SOLV is priced at $78.27, while CCEL trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas CCEL's P/E ratio is -10.55. In terms of profitability, SOLV's ROE is +0.31%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, SOLV is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check CCEL's competition here
SOLV vs CANO-WT Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, SOLV is priced at $78.27, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, SOLV is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check CANO-WT's competition here
SOLV vs AIH Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, SOLV is priced at $78.27, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas AIH's P/E ratio is -2.78. In terms of profitability, SOLV's ROE is +0.31%, compared to AIH's ROE of +1.16%. Regarding short-term risk, SOLV is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check AIH's competition here
SOLV vs CANO Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, SOLV is priced at $78.27, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas CANO's P/E ratio is -0.01. In terms of profitability, SOLV's ROE is +0.31%, compared to CANO's ROE of -1.49%. Regarding short-term risk, SOLV is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check CANO's competition here
SOLV vs FPCG Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, SOLV is priced at $78.27, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas FPCG's P/E ratio is 0.09. In terms of profitability, SOLV's ROE is +0.31%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, SOLV is more volatile compared to FPCG. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check FPCG's competition here
SOLV vs AMS Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, AMS has a market cap of 9.9M. Regarding current trading prices, SOLV is priced at $78.27, while AMS trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas AMS's P/E ratio is -6.69. In terms of profitability, SOLV's ROE is +0.31%, compared to AMS's ROE of -0.06%. Regarding short-term risk, SOLV is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check AMS's competition here
SOLV vs FTRP Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, SOLV is priced at $78.27, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas FTRP's P/E ratio is -1.22. In terms of profitability, SOLV's ROE is +0.31%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, SOLV is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check FTRP's competition here
SOLV vs MODV Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, SOLV is priced at $78.27, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas MODV's P/E ratio is -0.06. In terms of profitability, SOLV's ROE is +0.31%, compared to MODV's ROE of +1.36%. Regarding short-term risk, SOLV is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check MODV's competition here
SOLV vs GBNH Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, SOLV is priced at $78.27, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas GBNH's P/E ratio is -0.06. In terms of profitability, SOLV's ROE is +0.31%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, SOLV is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check GBNH's competition here
SOLV vs RHE Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, SOLV is priced at $78.27, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas RHE's P/E ratio is -1.79. In terms of profitability, SOLV's ROE is +0.31%, compared to RHE's ROE of -0.36%. Regarding short-term risk, SOLV is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check RHE's competition here
SOLV vs RHE-PA Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, SOLV is priced at $78.27, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, SOLV's ROE is +0.31%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, SOLV is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check RHE-PA's competition here
SOLV vs AIDX Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, AIDX has a market cap of 3.5M. Regarding current trading prices, SOLV is priced at $78.27, while AIDX trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas AIDX's P/E ratio is -1.16. In terms of profitability, SOLV's ROE is +0.31%, compared to AIDX's ROE of +0.79%. Regarding short-term risk, SOLV is less volatile compared to AIDX. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check AIDX's competition here
SOLV vs IMACW Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, SOLV is priced at $78.27, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas IMACW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to IMACW's ROE of +0.73%. Regarding short-term risk, SOLV is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check IMACW's competition here
SOLV vs CCM Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, CCM has a market cap of 627.6K. Regarding current trading prices, SOLV is priced at $78.27, while CCM trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas CCM's P/E ratio is -0.36. In terms of profitability, SOLV's ROE is +0.31%, compared to CCM's ROE of +0.07%. Regarding short-term risk, SOLV is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check CCM's competition here
SOLV vs NIVF Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, NIVF has a market cap of 262K. Regarding current trading prices, SOLV is priced at $78.27, while NIVF trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas NIVF's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, SOLV is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check NIVF's competition here
SOLV vs MNDR Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, MNDR has a market cap of 80.7K. Regarding current trading prices, SOLV is priced at $78.27, while MNDR trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas MNDR's P/E ratio is -0.08. In terms of profitability, SOLV's ROE is +0.31%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, SOLV is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check MNDR's competition here
SOLV vs NIVFW Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, NIVFW has a market cap of 48.9K. Regarding current trading prices, SOLV is priced at $78.27, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas NIVFW's P/E ratio is -0.01. In terms of profitability, SOLV's ROE is +0.31%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, SOLV is more volatile compared to NIVFW. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check NIVFW's competition here
SOLV vs NFH Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, NFH has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas NFH's P/E ratio is -19.75. In terms of profitability, SOLV's ROE is +0.31%, compared to NFH's ROE of -0.06%. Regarding short-term risk, SOLV is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check NFH's competition here
SOLV vs SLHG Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas SLHG's P/E ratio is -1.48. In terms of profitability, SOLV's ROE is +0.31%, compared to SLHG's ROE of N/A. Regarding short-term risk, SOLV is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check SLHG's competition here
SOLV vs SLHGP Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, SOLV's ROE is +0.31%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, SOLV is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check SLHGP's competition here
SOLV vs TLMD Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas TLMD's P/E ratio is -1.60. In terms of profitability, SOLV's ROE is +0.31%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, SOLV is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check TLMD's competition here
SOLV vs TLMDW Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas TLMDW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, SOLV is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check TLMDW's competition here
SOLV vs TVTY Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas TVTY's P/E ratio is 19.06. In terms of profitability, SOLV's ROE is +0.31%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, SOLV is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check TVTY's competition here
SOLV vs DCGOW Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas DCGOW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, SOLV is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check DCGOW's competition here
SOLV vs DVCR Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas DVCR's P/E ratio is 28.34. In terms of profitability, SOLV's ROE is +0.31%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, SOLV is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check DVCR's competition here
SOLV vs AFAM Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas AFAM's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, SOLV is less volatile compared to AFAM. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check AFAM's competition here
SOLV vs ATIP-WT Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, SOLV is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SOLV.Check ATIP-WT's competition here
SOLV vs KND Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, KND has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas KND's P/E ratio is -1.14. In terms of profitability, SOLV's ROE is +0.31%, compared to KND's ROE of -0.53%. Regarding short-term risk, SOLV is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check KND's competition here
SOLV vs HNGR Comparison July 2026
SOLV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.6B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.27, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.54, whereas HNGR's P/E ratio is 19.71. In terms of profitability, SOLV's ROE is +0.31%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, SOLV is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for SOLV.Check HNGR's competition here